Tango Therapeutics (TNGX) Operating Income Growth (1y) (2021 - 2026)

Tango Therapeutics (TNGX) Operating Income Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (1y) (Qtr)
1 Oculis Holding AG 66,019.86 Bn 66,019.58 Bn - -24.89%
2 Nanobiotix 1,909.20 Bn 1,909.14 Bn - -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn - -
4 BeOne Medicines 468.20 Bn 463.41 Bn 1.35 Bn 2,150.96%
5 Vertex Pharmaceuticals 122.50 Bn 115.26 Bn 2.59 Bn 80.62%
6 Regeneron Pharmaceuticals 70.15 Bn 61.39 Bn 3.31 Bn 8.65%
7 Belite Bio 62.66 Bn 62.66 Bn - -
8 Argenx Se 55.58 Bn 50.39 Bn 1.41 Bn 145.20%
9 Alnylam Pharmaceuticals 37.43 Bn 34.43 Bn 959.66 Mn 1,386.07%
10 Tango Therapeutics 3.81 Bn 3.66 Bn - -14.67%

Historic Data

Download Data
DateValue
Mar 31, 2026 -14.67%
Dec 31, 2025 -2.33%
Sep 30, 2025 142.80%
Jun 30, 2025 -38.63%
Mar 31, 2025 -0.65%
Dec 31, 2024 -16.84%
Sep 30, 2024 -28.30%
Jun 30, 2024 -27.12%
Mar 31, 2024 -39.52%
Dec 31, 2023 -14.55%
Sep 30, 2023 14.36%
Jun 30, 2023 7.76%
Mar 31, 2023 -19.33%
Dec 31, 2022 -39.04%
Sep 30, 2022 -52.91%
Jun 30, 2022 -453.16%
Mar 31, 2022 -110.07%
Dec 31, 2021 -12,017.20%
Sep 30, 2021 26.86%
Jun 30, 2021 -965,154.24%